Condition: Advanced Solid Tumor · Sponsor: Gilead Sciences
The goal of this clinical study is to learn more about the study drug, GS-5319, its dosing, safety and tolerability in adults with solid tumors, where the participants show a specific gene alteration in the tumor. The gene helps produce methylthioadenosine phosphorylase (MTAP) enzyme. MTAP enzyme helps in normal growth of cells. The primary objectives of the study are to assess the safety and tolerability of GS-5319 in participants with methylthioadenosine phosphorylase (MTAP)-deleted advanced solid tumors and to identify the maximum tolerated dose (MTD)/maximum administered dose (MAD) and/or the recommended dose for expansion (RDE).
This description comes directly from the study's public registry record.
Gilead Clinical Study Information Center · 1-833-445-3230 (GILEAD-0) · GileadClinicalTrials@gilead.com
Always discuss trial participation with your own doctor first.
| Beth Israel Deaconess Medical Center | Boston, Massachusetts, United States | Recruiting |
| START San Antonio | San Antonio, Texas, United States | Recruiting |
| NEXT Virginia | Fairfax, Virginia, United States | Recruiting |
| Yonsei University Severance Hospital | Seoul, South Korea | Recruiting |
| Seoul National University Hospital | Seoul, South Korea | Recruiting |
| Asan Medical Center | Seoul, South Korea | Recruiting |
| Samsung Medical Center | Seoul, South Korea | Recruiting |
| Vall d'Hebron Institute of Oncology (VHIO) | Barcelona, Spain | Recruiting |
| START Madrid - FJD - Hospital Fundación Jiménez Díaz - Phase I Clinical Trials Unit | Madrid, Spain | Recruiting |
| START - Centro Oncológico Clara Campal | Madrid, Spain | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07128303